Agenus | AGEN - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Agenus USD 14.67M 1.35M 2026-03
Amgen USD 95.64B 94.98B 2026-06
AstraZeneca USD 340M 144M 2026-06
Bristol-Myers Squibb USD 407M 4M 2026-06
CSL USD 215M 111M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 247M 7M 2026-06
GlaxoSmithKline GBP 121M 46M 2026-06
Glaxosmithkline GBP 192.73M 14.79M 2026-03
Incyte USD 582K 13K 2026-06
Intrexon USD 2K 5K 2024-06
J&J USD 43M 25M 2026-03
Jiangsu Hengrui CNY 254.59M 253.85M 2025-09
Karyopharm Therapeutics USD 12.55M 66K 2026-03
MacroGenics USD 4.89M 1.55M 2026-03
Merck EUR 137M 33M 2026-06
Merck USD 525M 46M 2026-06
Northwest Biotherapeutics USD 1.52M 276K 2024-03
Novartis USD 462M 119M 2026-06
Novavax USD 5.82M 342K 2025-12
Pfizer USD 667M 4M 2026-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sangamo BioSciences 97.56M 11.39M 2025-06
Veracyte USD 2K 1000 2023-12